Eric Rojas - Stoke Therapeutics Head Relations
| STOK Stock | USD 31.89 0.33 1.02% |
Insider
Eric Rojas is Head Relations of Stoke Therapeutics
| Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
| Phone | 781 430 8200 |
| Web | https://www.stoketherapeutics.com |
Stoke Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.052 % which means that it generated a profit of $0.052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1502 %, meaning that it created $0.1502 on every $100 dollars invested by stockholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.31. Return On Capital Employed is expected to rise to -0.48 this year. At this time, Stoke Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 58.2 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 224.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew May | Intellia Therapeutics | N/A | |
| MBA MD | Wave Life Sciences | 48 | |
| Glenn CPA | Intellia Therapeutics | 53 | |
| CPA MST | Ardelyx | 50 | |
| Robert Blanks | Ardelyx | 65 | |
| Karen Harrigan | Ardelyx | N/A | |
| RA MSc | Pharvaris BV | 45 | |
| Elliott Berger | BioCryst Pharmaceuticals | N/A | |
| James CFA | Novavax | 60 | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Susan Rodriguez | Ardelyx | 60 | |
| Kenneth CA | Zymeworks Common Stock | 64 | |
| Joan JD | Pharvaris BV | 60 | |
| Derrick Rossi | Intellia Therapeutics | N/A | |
| David Poon | Zymeworks Common Stock | N/A | |
| Annick Deschoolmeester | Pharvaris BV | 53 | |
| Gale Smith | Novavax | 74 | |
| Jonathan Rosin | Wave Life Sciences | N/A | |
| Stephen Lake | Wave Life Sciences | N/A | |
| Rachel Haurwitz | Intellia Therapeutics | 40 | |
| Paul Moore | Zymeworks Common Stock | 59 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.052 |
Stoke Therapeutics Leadership Team
Elected by the shareholders, the Stoke Therapeutics' board of directors comprises two types of representatives: Stoke Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stoke. The board's role is to monitor Stoke Therapeutics' management team and ensure that shareholders' interests are well served. Stoke Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stoke Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Jonathan JD, Corporate Counsel | ||
| Shamim MS, Senior Officer | ||
| Sara Besten, Chief Officer | ||
| Dawn Kalmar, Chief Partnerships | ||
| Eric Olson, Chief Officer | ||
| Doug Snow, Director Relations | ||
| FACC MD, Chief Officer | ||
| Joan Wood, Chief Officer | ||
| MS MBA, Chief Officer | ||
| Arthur Tzianabos, Interim Chairman | ||
| Huw Nash, Chief Officer | ||
| Isabel Aznarez, CoFounder Research | ||
| CPA ACA, Interim Director | ||
| Eric Rojas, Head Relations | ||
| Thomas Leggett, Chief Officer | ||
| Jason Hoitt, Chief Officer | ||
| Adrian Krainer, Independent CoFounder |
Stoke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stoke Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.052 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | (4.05) % | ||||
| Current Valuation | 1.58 B | ||||
| Shares Outstanding | 57.12 M | ||||
| Shares Owned By Insiders | 4.00 % | ||||
| Shares Owned By Institutions | 96.00 % | ||||
| Number Of Shares Shorted | 11.15 M | ||||
| Price To Book | 5.92 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.69 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.